Patient-derived cancer organoid culture is an important live material that reflects clinical heterogeneity. However, the limited amount of organoids available for each case as well as the considerable amount of time and cost to expand in vitro makes it impractical to perform high-throughput drug screening using organoid cultures from multiple patients. Here, we report an advanced system for the high-throughput screening of 2427 drugs using the cancer tissue-originated spheroid (CTOS) method.
Patient-derived cancer organoid culture is an important live material that reflects clinical heterogeneity. However, the limited amount of organoids available for each case as well as the considerable amount of time and cost to expand in vitro makes it impractical to perform high-throughput drug screening using organoid cultures from multiple patients. Here, we report an advanced system for the high-throughput screening of 2427 drugs using the cancer tissue-originated spheroid (CTOS) method.
In this system, we apply the CTOS method in an ex vivo platform from xenograft tumors, using machines to handle CTOS and reagents, and testing a CTOS reference panel of multiple CTOS lines for the hit drugs. CTOS passages in xenograft tumors resulted in minimal changes of morphological and genomic status, and xenograft tumor generation efficiently expanded the number of CTOS to evaluate multiple drugs. Our panel of colorectal cancer CTOS lines exhibited diverse sensitivities to the hit compounds, demonstrating the usefulness of this system for investigating highly heterogeneous disease.
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| INTRODUC TI ON
Inter-patient variations in sensitivity to therapeutics are a challenging issue in clinical practice, making it increasingly important to obtain tumor samples from individual cancer patients for both development of therapeutics and personalized medicine. To determine the portion of the population in which a drug will be effective and to identify biomarkers to demarcate potential responders, it is essential to develop systems in which drugs can be tested on materials retaining the heterogeneous characteristics of the original disease. [1] [2] [3] To assess the responses of cancer cells to various stimuli, including anti-cancer drugs, culture of cancer cells is required. Established cancer cell lines have historically been the pillar of such in vitro models. The simplicity and reproducibility of cancer cell lines enables drug testing and screening. 4, 5 However, prolonged in vitro culture of cancer cells promotes cell conversion, probably by selection or accumulation of genetic alterations, which is a caveat for the development of personalized therapeutic approaches and of new drugs. 5 Over the past decade, primary culture has been significantly improved by overcoming complicated procedures, poor reproducibility and uncontrolled co-existence of various cell types. 1, 6, 7 Modern cultures are expected to retain the characteristics of parental patient tumors, including drug sensitivity. One such approach is our recently developed method to efficiently prepare and culture organoids from primary tissues of colorectal cancers (CRC): the cancer tissue-originated spheroid (CTOS) method. 8 The principle behind the CTOS method is the maintenance of cell-cell contact throughout the preparation and culture process. This method provides the advantage of efficiently, rapidly and simply preparing pure and stable cancer cells as clusters. Some CTOS can form xenograft tumors in immuno-deficient mice, with morphology resembling that of the originated patient tumor. 8 Importantly, CTOS are simple to prepare, especially from xenograft tumors, enabling their reproducible application in multiple experiments. [9] [10] [11] [12] We previously demonstrated that CTOS exhibit heterogeneous responses to the tested drugs, 9, 12 which is critical in models for developing therapeutics and personalized medicine.
We have used the CTOS method to perform several small-scale drug screening trials, testing approximately 100 drugs with CTOS from CRC and endometrial cancer. [12] [13] [14] However, with manual experiments, it is practically impossible to perform high-throughput (HT)
screening to test thousands of drugs. Because cell-cell contact is retained throughout the procedure in the CTOS method, the welldeveloped screening method for 3D culture of established cell lines cannot be simply applied. In our present report, we describe a highly improved system to achieve HT screening of 2427 drugs. We confirmed that CTOS passages in xenograft tumors resulted in minimal changes in morphological and genomic status, and that xenograft tumor generation efficiently expanded the number of CTOS, enabling high throughput screening. Our panel of 30 CRC CTOS lines exhibited diverse sensitivities to the hit compounds, demonstrating the usefulness of this system for investigating highly heterogeneous cancers. 
| MATERIAL S AND ME THODS

| Cancer tissue-originated spheroid preparation
For both surgical specimens and xenografts, CTOS were prepared as previously described with slight modifications. 8 
| Library preparation and sequencing for exome analysis
In preparation for exome sequencing analyses, extracted DNA samples 
| Bioinformatics analysis of sequencing data
Sequenced reads were aligned with Burrows-Wheeler Aligner (BWA) ver. 0.7.12 to reference the human genome (hg19) or mouse genome (mm9). 16 The reads were excluded if they appeared to be derived from mouse cells based on the following criteria: reads were properly paired when aligned to the mouse genome but not when aligned to the human genome, or reads were more similar to the mouse genome than the human genome in the match length. GenomeAnalysisTK (GATK) 
| Assay plate preparation
Cancer tissue-originated spheroids were prepared as described above. After culturing for 24 hours, the CTOS were separated into 2 fractions by serially passing through 100-μm and 70-μm cell strainers (Corning): 70-100 μm (Fr.70-100) and >100 μm (Fr. > 100). Fr.70-100
was directly selected and plated. Fr. > 100 μm was mechanically disrupted, cultured for 1 day, and then selected and plated. An automated pipetting system (P5073; Eppendorf, Hamburg, Germany) was used to dispense 36 μL of STEMPRO hESC SFM into 384-well plates (PrimeSurface, Sumitomo Bakelite, Tokyo, Japan). Then, the 384-well plate was seeded with 1 CTOS per well using an automatic spheroid handler (CELL HANDLER https://global.yamaha-motor.
com/business/hc/index.html; Yamaha Motor, Iwata, Japan). The CTOS were selected according to size and appearance (see text for details), using images acquired by the internally equipped CCD camera in the spheroid handler. The area of each CTOS was measured using the pictures taken after plating.
| Drug panel for high-throughput screening
The library included 2427 drugs (Table S4) 
| Cancer tissue-originated spheroid viability assay
After addition of the drugs, CTOS were cultured in 5% CO 2 at 37°C 
| Determination of drug efficacy against monolayer cell lines
The drug efficacy against established cell lines in monolayer culture was assessed based on total cellular protein changes after 48 hours of drug treatment in five 10-fold serial dilutions (10 −4 , 10 −5 , 10 −6 , 10 −7 and 10 −8 mol/L, unless otherwise specified), measured by sulforhodamine B assay. Assays were performed in duplicate, and the half-maximal (50%) growth inhibitory concentration value (GI50) was calculated as previously described.
21,22
| Clustering analysis
The IC50/GI50 values of a drug across the examined cells (CTOS or cell lines) were log-transformed and centered by subtracting the mean 
| Statistical analysis
Correlations were analyzed by Pearson's correlation using GraphPad Prism 6 software (San Diego, CA, USA). A P-value of <0.05 was considered significant.
| RE SULTS
| Generating cancer tissue-originated spheroidderived xenografts without remarkable alteration of histological and genetic profiles
To perform high-throughput (HT) screening on patient-derived materials and to evaluate diversity among them, we established CRC CTOS lines via in vivo passaging. CTOS were prepared from xenograft tumors, transplanted to other mice, and freeze-stocked. When a CTOS successfully generated xenograft tumors in over 2 passages, and left sufficient freeze stocks, it was deemed a successfully established CTOS line.
We next evaluated how well CRC CTOS retained characteristics of their originated patient tumors after in vivo passages. Established cell lines reportedly lose characteristics of the original tumors, 5 accumulating mutations and losing morphological features even in xenograft tumors. 8 We compared histology between xenograft tumors at different passages and the original patient tumors ( Figure 1A) , and found good retention of morphological characteristics of the original tumors, especially differentiation status, which was also confirmed in lung cancer ( Figure S1A and Table S5 ). We also performed whole-exome sequencing to monitor genomic alterations in 2 CRC CTOS during passages ( Figure 1B ). Although each line showed a different number of mutations, all CTOS lines showed only a marginal increase in mutation during in vivo passages, which was also confirmed in 2 CTOS of lung cancer ( Figure S1B ). Overall, our observations verified that CTOS lines met the quality requirements for use as a platform for HT screening and evaluation of diversity.
| High-throughput screening of 2427 drugs on 2 colorectal cancer tissue-originated spheroid lines
Unlike established cell lines, from which homogenous spheroids can be prepared, CTOS are heterogeneous in terms of shape and size. It is practically impossible to manually select and dispense CTOS within a specific range of size and quality into each well to test thousands of drugs. Thus, we used an automatic system to select CTOS meeting morphological criteria, and to dispense them individually. CTOS were selected based on size (70-100 μm) to minimize the effect of hypoxia after growth and on appearance (transparency) to exclude the clusters of dead cells (Figure 2A ). Two CRC lines were used for highthroughput screening: the fast-growing C45 line and the slow-growing C132 line. Figures 2B,C show the variations of CTOS size and growth.
We screened a total of 2427 drugs (Table S4) at relatively low doses (10 and 100 nmol/L) for their ability to suppress cancer cell growth ( Figure 2D ). Of these 2427 drugs, we identified 15 (.6%) hit drugs that inhibited CTOS viability down to 40% of control (Table 1) , of which 8 drugs were effective against both lines, 2 drugs against C45 alone, and 5 drugs against C132 alone; 10 drugs were anti-cancer reagents and 7
were FDA-approved.
| Hit drug evaluation using a panel of 30 colorectal cancer tissue-originated spheroid
To evaluate the diversity of sensitivity among the 15 hit drugs in various CTOS lines, we used a CRC CTOS panel comprising 30 lines (Tables   S1, S2 ). We had a 100% success rate Figure 3C . D, Ranks of the sensitivity of CTOS lines toward bortezomib and carfilzomib (left), docetaxel and cabazitaxel (middle), and docetaxel and bortezomib (right) are presented in diagrams. R-value and P-value were analyzed by Spearman's rank correlation correlation ( Figure 4D, right panel) . These data indicate that the assay correctly reflected the mode of action.
| Diversity of sensitivity among cancer tissueoriginated spheroids from the colorectal cancer panel
We next compared our results in CRC CTOS with the findings of JFCR39, which is a panel of 39 human cancer cell lines coupled with an NCI60-based drug-activity database. 22, 23 We generated a log-log scatter plot graph by plotting the average IC50 values (−log)
for the 15 drugs in the CRC CTOS panel on the horizontal axis, and in CTOS assay was strikingly higher than that between cancer cell lines in JFCR assay for all examined candidate drugs ( Figure 5B ). This result supports that the CTOS panel is a suitable platform for studying the extent of response heterogeneity, although the reason of the difference might be due to the different methods used, IC50 and GI50. We further evaluated the sensitivity of each CTOS line to different drugs. We ranked the sensitivity of 30 individual lines towards each FDA-approved drug ( Figure S4 ). The ranking profile differed for individual lines ( Figure 5C ).
| D ISCUSS I ON
In most reports of high-throughput screening in 3D cultured cells, spheroids have been generated as the aggregates of established cell lines. 4 Organoid methods have previously been used for smaller scale screenings of 16-160 drugs. [24] [25] [26] To our knowledge, this is the and stability compared to the primary cells dissociated into single cells. 8, 27 These advantages of CTOS enabled the high throughput screening using 3D and ex vivo culture.
The CTOS method supports ex vivo applications of mouse xenografts, including high-throughput screening, as in our present study, genetic manipulation of cancer cells, 10, 11 and detailed analysis of intracellular signaling in response to various stimuli. 9, 12 Notably, CTOS can be freeze-stocked with an excellent recovery rate, helping to avoid over-passage of patient-derived xenografts. Here we demonstrated that a CTOS ex vivo assay can also be applied to PDX ( Figure 5C ). It is costly and time-consuming to expand CTOS in vitro.
However, large numbers of CTOS can be prepared from a xenograft tumor within approximately 1 month ( Figure 3A) . Thus, the CTOS method complements mouse xenograft methods. We demonstrated that some genomic changes occurred in CTOS throughout 5 passages via mouse xenografts ( Figures 1B, S1B ), such as passaged tumors of PDX. 28 One should keep in mind this slight genomic changes might affect the results of sensitivity assay and can be the cause for a discrepant result with patient's clinical response, when clinical application is the subject of a study.
Our present results showed that drug sensitivity substantially clinical trials specifically in the cases of an EGFR tyrosine kinase inhibitor in lung cancer 9 and an anti-EGFR antibody in colorectal cancer. 12 However, the clinical relevance of the CTOS sensitivity assay should be further assessed in prospective clinical trials, such as a recent study that compared the drug responses of patient-derived gastrointestinal organoids with the responses of the patients in the clinic. 29 It may be necessary to optimize the culture conditions for each drug 9, 12 to better reflect the clinical responses of individual patients to the drug.
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